|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA is an important tumor marker for colorectal and some other carcinomas.
|
10202129 |
1999 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) has been suggested as a metastatic activator in colorectal carcinoma, whereas the E-cadherin expression is downregulated in a variety of carcinomas.
|
14592671 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is a 180-kDa glycoprotein expressed on most gastrointestinal carcinomas.
|
1860736 |
1991 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is expressed on human colon carcinomas, is well characterized, and continues to be a promising target for cancer immunotherapy in humans.
|
18812201 |
2008 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is a potential target for antigen-specific immunotherapy, as it is frequently overexpressed in human carcinomas.
|
20386466 |
2010 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA concentrations exceeding 5 ng/mL cut-off point indicated carcinomas, regardless of pleural involvement, which gave a sensitivity of 62% and specificity of 100% for carcinoma.
|
31028099 |
2019 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
|
27581603 |
2016 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas.
|
18937552 |
2009 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
AA-Cur elicited moderate anti-tumor activity toward colon MC38-CEA or breast 4T1 carcinomas.
|
31564877 |
2019 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Antitumor studies were performed in CEA-Tg mice bearing CEA-transfected MC38 murine colon carcinomas (MC38-CEA), treated either concurrently or sequentially with sunitinib and vaccine.
|
21633954 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is expressed on approximately 95% of colorectal, gastric, and pancreatic tumors, and on the majority of breast, non-small cell lung, and head and neck carcinomas.
|
11289125 |
2001 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Construction, expression and characterization of a dual cancer-specific fusion protein targeting carcinoembryonic antigen in intestinal carcinomas.
|
19686851 |
2010 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas.
|
8386136 |
1993 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Downregulation of carcinoembryonic antigen-related cell adhesion molecule (CEACAM1), a cell adhesion molecule with tumor suppressing properties has been observed in a high percentage of carcinomas of the endometrium and other malignancies.
|
16332726 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
However, assays of the tissue CEA content in six histologically verified adenomas showed values similar to those of overt colonic carcinomas.
|
1202622 |
1975 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Human carcinoembryonic antigen (CEA) is a well-characterized oncofetal glycoprotein whose overexpression by human carcinomas has been a target for cancer immunotherapy.
|
9973217 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunodiffusion of perchloric acid extracts of CEA-like material from heterozygote carrier blood indicated that the CEA-like material, which was elevated in homozygotes and heterozygotes for CF, showed only partial identity with two separate CEA preparations obtained from colon carcinomas and was not identical to either A, B, or O(H) blood group substances.
|
824719 |
1976 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, the newly identified helper T-cell epitope was found to overlap with a previously described HLA-A24-restricted CTL epitope, CEA(652-660), which could facilitate the development of a therapeutic vaccine capable of eliciting both CTL and T helper responses in patients suffering from epithelial carcinomas.
|
12374692 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
MFE-23-his scFv antibody localizes in CEA-producing carcinomas.
|
10815889 |
2000 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
On the other hand, 85% of non-small cell lung carcinomas stained for CEA, whereas none of the ovarian clear cell carcinomas did (P < 0.001).
|
17413979 |
2007 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
On the other hand, slightly higher CEA-specific T cell responses were observed in cancer patients with CEA-expressing carcinomas than in healthy blood donors.
|
11129322 |
2000 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that mammaglobin B and CEA could be useful RT-PCR markers for the detection of lymph node micrometastases in biliary tract carcinomas.
|
10873083 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PANVAC consists of rV, rF-CEA-MUC1-TRICOM; the expression of the two pan-carcinoma transgenes CEA and MUC-1 renders PANVAC vaccination applicable for therapeutic applications for a range of human carcinomas.
|
22595052 |
2012 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
|
15613691 |
2005 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Pre-operative CEA levels were measured in 100 patients with large bowel carcinomas with different DNA ploidy pattern and serial post-operative determinations performed in the 64 who had been operated for cure.
|
3816909 |
1986 |